Dateline City:
WUPPERTAL, Germany & WHITEHOUSE STATION, N.J.
WUPPERTAL, Germany & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--AiCuris and Merck (NYSE:MRK), known as MSD outside the United States and
Canada, today announced the publication of results from a Phase 2
clinical trial evaluating the safety and efficacy of letermovir, an
investigational, oral antiviral agent for the prevention of human
cytomegalovirus (CMV) infection in patients receiving bone marrow
transplant.
Language:
English
Contact:
MerckMedia:Caroline Lappetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orAiCurisMedia:Katja Woestenhemke, +49-202-317-63-1176
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more